Investigational Drug Information for HSG4112
What is the development status for investigational drug HSG4112?
HSG4112 is an investigational drug.
There have been 5 clinical trials for HSG4112.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 31st 2022.
The most common disease conditions in clinical trials are Overweight and [disabled in preview]. The leading clinical trial sponsors are Glaceum, Seoul National University Hospital, and Kyungpook National University Hospital.
There are four US patents protecting this investigational drug.
Summary for HSG4112
| US Patents | 4 |
| International Patents | 0 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2022-01-31) |
| Vendors | 19 |
Recent Clinical Trials for HSG4112
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses | Seoul National University Hospital | Phase 1 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses | Glaceum | Phase 1 |
| A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients | Gangnam Severance Hospital | Phase 2 |
Clinical Trial Summary for HSG4112
Top disease conditions for HSG4112
Top clinical trial sponsors for HSG4112
US Patents for HSG4112
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| HSG4112 | ⤷ Start Trial | Method for synthesizing 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2.3-f]chromene derivative and optical isomer of thereof | Glaceum Inc | ⤷ Start Trial |
| HSG4112 | ⤷ Start Trial | 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivative and method for synthesizing optical isomer thereof | Glaceum Inc | ⤷ Start Trial |
| HSG4112 | ⤷ Start Trial | Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same | Glaceum Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
